You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget

    SBC: DOTY SCIENTIFIC, INC.            Topic: NIA

    ? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Aminoglycosides with reduced ototoxicity

    SBC: NUBAD LLC            Topic: NIAID

    PROJECT SUMMARY Aminoglycosides are one of the cheapest and well known antibiotics in clinical use for over years but one of the major limitations in their use is their ototoxicity We are developing fast and low cost methods to develop aminoglycosides with anti ribosomal activities and reduced toxicity In this project we will identify novel aminoglycoside antibacterials that show reduced ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. A Rapid assay for RNA targeted drugs: Instrumentation Supplement

    SBC: NUBAD LLC            Topic: 300

    DESCRIPTION provided by applicant Some of the most significant therapies that treat disease target nucleic acids Drugs that target nucleic acid include cancer drugs antibiotics and antivirals Combined these classes of drugs have annual sales worldwide of $ billion Antibiotics that target nucleic acids account for $ billion of the $ billion of sales annuall for all antibiotics an ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  4. A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: 300

    DESCRIPTION provided by applicant Problem Lower gastrointestinal bleeding is a significant medical problem in the United States accounting for more than hospital admissions and tens of billions of dollars of healthcare spending annually It is common for bleeding from a single site to stop and restart multiple times The three modalities now used to diagnose and locate gastrointestina ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Assessing the Bite Counter as a Tool for Food Intake Monitoring: Phase II

    SBC: BITE TECHNOLOGIES, LLC            Topic: 300

    DESCRIPTION provided by applicant Self monitoring has been described as the andquot cornerstone of the behavioral treatment of obesityandquot Consistent self monitoring of energy intake is associated with improved dietary adherence and weight loss and maintenance The problem is that individuals are notoriously bad at self monitoring their intake and suffer from an underreporting bias The s ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Cancer Imaging and Therapy Platform

    SBC: BIOINVISION INC            Topic: 102

    Summary We will create a preclinical quantitative Cancer Imaging and Therapy Platform CITP which will allow one to study cancer biology and optimize pipelines of technologies imaging agents imaging methods targeted nano therapeutics tumor models etc especially for metastatic and invasive cancers Today primary tumor mass es are clinically controlled with surgical drug and radiatio ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome

    SBC: ATHERSYS, INC.            Topic: NIAAA

    DESCRIPTION (provided by applicant): This is a resubmission of a Phase I-Phase II Fast-Track application for the clinical use of MultiStem in patients with acute respiratory distress syndrome (ARDS). ARDS is defined as acute onset hypoxemia, bilateral radiographic pulmonary infiltrates and lack of atrial pressure hypertension. A novel and exiting possibility is the use of cells as part of the ther ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome

    SBC: ATHERSYS, INC.            Topic: NIAAA

    DESCRIPTION provided by applicant This is a resubmission of a Phase I Phase II Fast Track application for the clinical use of MultiStem in patients with acute respiratory distress syndrome ARDS ARDS is defined as acute onset hypoxemia bilateral radiographic pulmonary infiltrates and lack of atrial pressure hypertension A novel and exiting possibility is the use of cells as part of the ther ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Combinatorial RXR-based therapeutics for Alzheimer's disease

    SBC: REXCEPTOR, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): The principle objective of this application is the development of safer and more effective combinatorial therapy for AD. ReXceptor, Inc. is developing new therapeutics for the treatment of AD based on stimulating the physiological clearance mechanisms of soluble forms of A from the brain. Bexarotene is an agonist of the ligand-activated transcription factor, r ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Corneal Endothelial Stem Cells for Treatment of Corneal Endothelial Dystrophies

    SBC: RASHMIVU LLC            Topic: N

    DESCRIPTION provided by applicant Corneal clouding caused by failure of the corneal endothelial deturgesence mechanism affects over million people in the US and well over million people worldwide It is the most common corneal disease and is historically a common cause of blindness Surgical treatment by corneal grafting has been successful when available but is limited by the availabili ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government